Cancer stem cells and the cell cycle: Targeting the drive behind breast cancer

Expert Review of Anticancer Therapy

Volumn 9, Issue 3, 2009, Pages 275-279

  Velasco Velázquez, Marco A ^a   Yu, Zuoren ^b   Jiao, Xuanmao ^b   Pestell, Richard G ^b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA6 INTEGRIN; BRCA1 PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; HERMES ANTIGEN; MICRORNA; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA1; WT1 PROTEIN;

BREAST CANCER; CANCER INHIBITION; CANCER STEM CELL; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL DIVISION; CELL EXPANSION; CELL FATE; CELL LINEAGE; CELL MIGRATION; CELL PROLIFERATION; CELL RENEWAL; EDITORIAL; HEMATOPOIETIC STEM CELL; HUMAN; MITOCHONDRIAL RESPIRATION; TARGET CELL; TRANSLATION REGULATION;

BREAST NEOPLASMS; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; CYCLINS; FEMALE; HUMANS; NEOPLASTIC STEM CELLS;

EID: 65749098800     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.9.3.275     Document Type: Editorial

References (55)

1. Vermeulen L, Sprick MR, Kemper K, Stassi G, Medema JP. Cancer stem cells - old concepts, new insights. Cell Death Differ. 15(6), 947-958 (2008).
2. Ponti D, Costa A, Zaffaroni N et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 65(13), 5506-5511 (2005).
3. Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367(6464), 645-648 (1994).
4. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100(7), 3983-3988 (2003).
5. Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature 432(7015), 396-401 (2004).
6. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65(23), 10946-10951 (2005).
7. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445(7123), 106-110 (2007).
8. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/ progenitor cells. Biochem. Biophys. Res. Commun. 351(4), 820-824 (2006).
9. Yin S, Li J, Hu C et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int. J. Cancer 120(7), 1444-1450 (2007).
10. Eramo A, Lotti F, Sette G et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15(3), 504-514 (2008).
11. Uchida N, Buck DW, He D et al. Direct isolation of human central nervous system stem cells. Proc. Natl Acad. Sci. USA 97(26), 14720-14725 (2000).
12. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu. Rev. Med. 58, 267-284 (2007).
13. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 445(7123), 111-115 (2007).
14. Neganova I, Lako M. G1 to S phase cell cycle transition in somatic and embryonic stem cells. J. Anat. 213(1), 30-44 (2008).
15. Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR. A stem cell molecular signature. Science 298(5593), 601-604 (2002).
16. Kohlmaier A, Edgar BA. Proliferative control in Drosophila stem cells. Curr. Opin. Cell. Biol. 20(6), 699-706 (2008).
17. Wang Y, Baskerville S, Shenoy A, Babiarz JE, Baehner L, Blelloch R. Embryonic stem cell-specific microRNAs regulate the G1-S transition and promote rapid proliferation. Nat. Genet. 40(12), 1478-1483 (2008).
18. Yu Z, Wang C, Wang M et al. A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J. Cell. Biol. 182(3), 509-517 (2008).
19. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 10(2), R25 (2008).
20. Corti S, Locatelli F, Papadimitriou D et al. Identification of a primitive brain-derived neural stem cell population based on aldehyde dehydrogenase activity. Stem Cells 24(4), 975-985 (2006).
21. Hess DA, Meyerrose TE, Wirthlin L et al. Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood 104(6), 1648-1655 (2004).
22. Ginestier C, Hur MH, Charafe-Jauffret E et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5), 555-567 (2007).
23. Vassilopoulos A, Wang RH, Petrovas C, Ambrozak D, Koup R, Deng CX. Identification and characterization of cancer initiating cells from BRCA1 related mammary tumors using markers for normal mammary stem cells. Int. J. Biol. Sci. 4(3), 133-142 (2008).
24. Ambler CA, Maatta A. Epidermal stem cells: location, potential and contribution to cancer. J. Pathol. 217(2), 206-216 (2009).
25. Stingl J, Eirew P, Ricketson I et al. Purification and unique properties of mammary epithelial stem cells. Nature 439, 993-997 (2006).
26. Kozar K, Ciemerych MA, Rebel VI et al. Mouse development and cell proliferation in the absence of D-cyclins. Cell 118(4), 477-491 (2004).
27. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: cyclin D1: normal and abnormal functions. Endocrinology 145(12), 5439-5447 (2004).
28. cip1/waf1. Science 287(5459), 1804-1808 (2000).
29. Caldon CE, Daly RJ, Sutherland RL, Musgrove EA. Cell cycle control in breast cancer cells. J. Cell Biochem. 97(2), 261-274 (2006).
30. Cip1/WAF1 alters keratinocyte growth and differentiation and promotes ras-tumor progression. Genes Dev. 10(23), 3065-3075 (1996).
31. Waf1/Cip1-deficient mice. Cancer Res. 61(16), 6234-6238 (2001).
32. WAF1/CIP1 deficiency on MMTV-ras and MMTV-myc mammary tumor properties. Cancer Res. 62(7), 2077-2084 (2002).
33. Cip1/Waf1 in maintaining normal hematopoietic stem cell functioning. Stem Cells 25(4), 836-843 (2007).
34. Choudhury AR, Ju Z, Djojosubroto MW et al. Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. Nat. Genet. 39(1), 99-105 (2007).
35. Kip1 repression of ErbB2-induced mammary tumor growth in transgenic mice involves Skp2 and Wnt/β-catenin signaling. Cancer Res. 66(17), 8529-8541 (2006).
36. Besson A, Hwang HC, Cicero S et al. Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev. 21(14), 1731-1746 (2007).
37. Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev. 18(8), 862-876 (2004).
38. Kouvaraki M, Gorgoulis VG, Rassidakis GZ et al. High expression levels of p27 correlate with lymph node status in a subset of advanced invasive breast carcinomas: relation to E-cadherin alterations, proliferative activity, and ploidy of the tumors. Cancer 94(9), 2454-2465 (2002).
39. Ghiaur G, Lee A, Bailey J, Cancelas JA, Zheng Y, Williams DA. Inhibition of RhoA GTPase activity enhances hematopoietic stem and progenitor cell proliferation and engraftment. Blood 108(6), 2087-2094 (2006).
40. Kip1. Cancer Res. 66(20), 9986-9994 (2006).
41. Sankaran VG, Orkin SH, Walkley CR. Rb intrinsically promotes erythropoiesis by coupling cell cycle exit with mitochondrial biogenesis. Genes Dev. 22(4), 463-475 (2008).
42. Wang C, Li Z, Lu Y et al. Cyclin D1 repression of nuclear respiratory factor 1 integrates nuclear DNA synthesis and mitochondrial function. Proc. Natl Acad. Sci. USA 103(31), 11567-11572 (2006).
43. Ravandi F, Estrov Z. Eradication of leukemia stem cells as a new goal of therapy in leukemia. Clin. Cancer Res. 12(2), 340-344 (2006).
44. Sridhar J, Pattabiraman N, Pestell RG. CDK Inhibitors as Anticancer Agents. In: Enzyme Inhibitors. Yue E, Smith PJ (Eds.) CRC Press, FL, USA (2005).
45. Li L, Xie T. Stem cell niche: structure and function. Annu. Rev. Cell Dev. Biol. 21, 605-631 (2005).
46. Spradling A, Drummond-Barbosa D, Kai T. Stem cells find their niche. Nature 414(6859), 98-104 (2001).
47. Yin T, Li L. The stem cell niches in bone. J. Clin. Invest. 116(5), 1195-1201 (2006).
48. Wels J, Kaplan RN, Rafii S, Lyden D. Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev. 22(5), 559-574 (2008).
49. Katiyar S, Jiao X, Wagner E, Lisanti MP, Pestell RG. Somatic excision demonstrates c-Jun induces cellular migration and invasion through induction of stem cell factor. Mol. Cell Biol. 27(4), 1356-1369 (2007).
50. Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res. 66(9), 4553-4557 (2006).
51. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea - a paradigm shift. Cancer Res. 66(4), 1883-1890 (2006).
52. Bourguignon LY, Peyrollier K, Xia W, Gilad E. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J. Biol. Chem. 283(25), 17635-17651 (2008).
53. Godar S, Ince TA, Bell GW et al. Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell 134(1), 62-73 (2008).
54. Cariati M, Naderi A, Brown JP et al. α-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int. J. Cancer 122(2), 298-304 (2008).
55. Platt VM, Szoka FC Jr. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol. Pharm. 5(4), 474-486 (2008).